EchoSolv HF regulatory update
Filed with ASX · · 1 page · English
Summary by 6ix AI
Echo IQ Limited provides a regulatory update regarding EchoSolv HF, stating that the FDA has upheld its previous determination of 'not substantially equivalent' for the product. The company is exploring options with its regulatory and legal advisors, including a potential new submission to the FDA. Echo IQ emphasizes that this decision does not impact EchoSolv AS, which remains FDA-cleared and available in the US. The company will continue to inform the market in line with its disclosure obligations.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from EchoIQ
- Trading Halt
- Pause in Trading
- Bell Potter Healthcare Conference Presentation
- Dr Vasum Peiris Appointed as Chief Medical Officer
- Notification regarding unquoted securities - EIQ
Later from EchoIQ
All EchoIQ news releasesFollow EchoIQ into a list and get an email when it puts out news.
Follow EchoIQ